Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
Launched by SUN YAT-SEN UNIVERSITY · Oct 2, 2021
Trial Information
Current as of June 06, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective three cycles of chemotherapy, known as CEV, are for treating high-risk retinoblastoma in children who have had one eye removed (a procedure called enucleation). The study focuses on patients with Stage I retinoblastoma, which is an early stage of this eye cancer, to see if this treatment can help improve their outcomes after surgery.
To participate in the trial, children must have a confirmed diagnosis of retinoblastoma, have undergone enucleation of the affected eye, and be able to provide consent for the study. They must not have any previous treatments for retinoblastoma in the study eye or have participated in other clinical trials recently. If eligible, participants will receive the chemotherapy and will be monitored closely throughout the study to track their progress and any side effects. This trial is currently recruiting participants of all ages and genders, aiming to improve treatments for this serious condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability to provide written informed consent and comply with study assessments for the full duration of the study.
- • Definite pathology signs of retinoblastoma, Stage I base on International Retinoblastoma Staging System.
- • Received enucleation in the study eye.
- • Monocular retinoblastoma.
- Exclusion Criteria:
- • Any previous disease in the study eye.
- • Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).
- • History of chemical intervention for retinoblastoma in the study eye.
About Sun Yat Sen University
Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Huasheng Yang, M.D, PHD
Study Chair
Zhongshan Ophthalmic Center, Sun Yat-sen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials